UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 17.06.2019
- 20
United Bankers Corporation | NOTIFICATION |
17.06.2019 at 18:30
UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 17.06.2019
Date | 17.06.2019 | |
Exchange transaction | Buy | |
Share class | UNIAV | |
Amount | 50 | |
Average price/share | 7.7000 | EUR |
Highest price/share | 7.7000 | EUR |
Lowest price/share | 7.7000 | EUR |
Total price | 385.00 | EUR |
The shares held by United Bankers Corporation on 17.06.2019:
UNIAV 22,667 |
On behalf of United Bankers Corporation
Skandinaviska Enskilda Banken AB (Publ)
Antti Salakka Mikko Virtanen
For more information, please contact:
Patrick Anderson, toimitusjohtaja, United Bankers Oyj
Sähköposti: [email protected]
Puhelin: 0400 244 544,09 25 380 236
www.unitedbankers.fi
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: United Bankers Oyj via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: United Bankers Oyj via Globenewswire
GlobeNewsWire Europe
GlobeNewswire Europe, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Lastest news
- Shareholder Alert: Ademi LLP investigates whether HashiCorp Inc. has obtained a Fair Price in its transaction with IBM
- Marex Group plc Announces Pricing of Initial Public Offering
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- TransAlta Declares Dividends
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST